Opus Genetics, Inc.

Pharmaceutical Preparations

IRD Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001228627 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$502.50M
83,195,823 shares Covers every share class this company has on file.
Insiders on file
12
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$34.69M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
6.90%
insider-held value divided by market capitalisation

What Opus Genetics, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$14.20M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$49.59M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
27
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Opus Genetics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Opus Genetics, Inc..
Insider Reported role Shares Value Last action
Officers 2
Ashwath Jayagopal Other Executive 516,775 $2.41M S Open-market sale Apr 23, 2026 position reported
Joseph K. Schachle COO 300,781 $1.40M S Open-market sale Jul 23, 2026 position reported
Officers who also sit on the board 4
Cam Gallagher CFO 2,074,430 $9.69M M Option exercise or conversion Sep 8, 2026 position reported
George Magrath CEO 1,750,855 $8.18M F Shares withheld for taxes Sep 9, 2026 position reported
Benjamin R. Yerxa President 719,005 $3.36M S Open-market sale Jul 23, 2026 position reported
Robert E Gagnon CFO 600,000 $2.80M S Open-market sale Sep 3, 2026 position reported
Directors 6
Richard J Rodgers Richard J Rodgers Board Member 318,655 $1.49M A Grant or award Apr 20, 2026 position reported
Sean Ainsworth Board Member 297,325 $1.39M A Grant or award Apr 20, 2026 position reported
James S. J. Manuso Board Member 292,951 $1.37M A Grant or award Apr 20, 2026 position reported
Jean Bennett Board Member 234,652 $1.10M A Grant or award Apr 20, 2026 position reported
Susan Benton Board Member 219,527 $1.03M A Grant or award Apr 20, 2026 position reported
Adrienne L Graves Board Member 103,147 $481.7K A Grant or award Apr 20, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Robert E Gagnon sold 28,000 Opus Genetics, Inc. (IRD) shares for $127,120 on Sep 3, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Robert E Gagnon sold 28,000 Opus Genetics, Inc. (IRD) shares for $127,120 on Sep 3, 2026
Date Insider Transaction Shares Price Value Filing
Sep 3, 2026 Robert E Gagnon S Open-market sale 28,000 held after: 556,375 $4.54 $127,120 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Robert E Gagnon sold 7,783 Opus Genetics, Inc. (IRD) shares for $22,960 on Jul 23, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Robert E Gagnon sold 7,783 Opus Genetics, Inc. (IRD) shares for $22,960 on Jul 23, 2026
Date Insider Transaction Shares Price Value Filing
Jul 23, 2026 Robert E Gagnon S Open-market sale 7,783 held after: 584,375 $2.95 $22,960 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Robert E Gagnon sold 7,842 Opus Genetics, Inc. (IRD) shares for $40,622 on Apr 23, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Robert E Gagnon sold 7,842 Opus Genetics, Inc. (IRD) shares for $40,622 on Apr 23, 2026
Date Insider Transaction Shares Price Value Filing
Apr 23, 2026 Robert E Gagnon S Open-market sale 7,842 held after: 592,158 $5.18 $40,622 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 72 rows we hold, 8 are open-market purchases (P) and 13 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Opus Genetics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Sep 9, 2026 George Magrath F Shares withheld for taxes 75,541 $5.97 $451.0K SEC filing ↗
Sep 9, 2026 George Magrath M Option exercise or conversion 392,157 $1.15 $451.0K SEC filing ↗
Sep 8, 2026 Cam Gallagher M Option exercise or conversion 784,314 $1.15 $902.0K SEC filing ↗
Sep 3, 2026 Robert E Gagnon S Open-market sale 28,000 $4.54 $127.1K SEC filing ↗
Jul 23, 2026 Benjamin R. Yerxa S Open-market sale 7,429 $2.97 $22.1K SEC filing ↗
Jul 23, 2026 Joseph K. Schachle S Open-market sale 4,644 $2.94 $13.7K SEC filing ↗
Jul 23, 2026 George Magrath S Open-market sale 9,475 $2.95 $28.0K SEC filing ↗
Jul 23, 2026 Robert E Gagnon S Open-market sale 7,783 $2.95 $23.0K SEC filing ↗
Apr 23, 2026 Benjamin R. Yerxa S Open-market sale 7,470 $5.24 $39.1K SEC filing ↗
Apr 23, 2026 Joseph K. Schachle S Open-market sale 4,697 $5.22 $24.5K SEC filing ↗
Apr 23, 2026 George Magrath S Open-market sale 9,511 $5.22 $49.6K SEC filing ↗
Apr 23, 2026 Ashwath Jayagopal S Open-market sale 7,542 $5.19 $39.1K SEC filing ↗
Apr 23, 2026 Robert E Gagnon S Open-market sale 7,842 $5.18 $40.6K SEC filing ↗
Apr 20, 2026 Richard J Rodgers A Grant or award 24,367 $0.00 $0 SEC filing ↗
Apr 20, 2026 James S. J. Manuso A Grant or award 24,367 $0.00 $0 SEC filing ↗
Apr 20, 2026 Adrienne L Graves A Grant or award 24,367 $0.00 $0 SEC filing ↗
Apr 20, 2026 Cam Gallagher A Grant or award 24,367 $0.00 $0 SEC filing ↗
Apr 20, 2026 Susan Benton A Grant or award 24,367 $0.00 $0 SEC filing ↗
Apr 20, 2026 Jean Bennett A Grant or award 24,367 $0.00 $0 SEC filing ↗
Apr 20, 2026 Sean Ainsworth A Grant or award 24,367 $0.00 $0 SEC filing ↗
Mar 16, 2026 Ashwath Jayagopal S Open-market sale 3,719 $5.12 $19.0K SEC filing ↗
Mar 16, 2026 Joseph K. Schachle S Open-market sale 3,719 $5.25 $19.5K SEC filing ↗
Mar 16, 2026 George Magrath S Open-market sale 24,438 $5.21 $127.3K SEC filing ↗
Feb 12, 2026 Ashwath Jayagopal F Shares withheld for taxes 5,313 $3.39 $18.0K SEC filing ↗
Jan 22, 2026 Ashwath Jayagopal A Grant or award 400,000 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 2 filers hold a position

Who owns Opus Genetics, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 2 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in Opus Genetics, Inc.

Funds, trusts and companies that disclose an ownership position in Opus Genetics, Inc..
Owner Reported role Shares Filed
Foundation Fighting Blindness Retinal Degeneration Fund Director,Other,TenPercentOwner 5,492,171 joint
Foundation Fighting Blindness, Inc. Director,Other,TenPercentOwner 5,492,171 joint

See the full ownership map — every entity that files as an owner of a US public company.

Subsidiaries — 1 legal entity

Subsidiaries of Opus Genetics, Inc.

1 legal entity named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries Opus Genetics, Inc. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
OPUSTX, LLC Delaware
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Opus Genetics, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Opus Genetics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.